A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.

Patrick Cheung, Georg A. Bjarnason, Scott North et al.|Journal of Clinical Oncology|2020

Cited by 9